Both medications are excellent. The right choice depends on your goals, budget, and tolerance. Here is the honest comparison — efficacy data, dosing, side effects, and cost — written by a physician who prescribes both daily.
Tirzepatide produces greater average weight loss but costs more and has a newer safety track record. Semaglutide is more established, costs roughly half as much, and still produces clinically significant weight loss for most patients. Both are first-line options. There is no wrong answer.
Until 2025, the question "which is more effective" was answered by indirect comparison across different clinical trials. That changed with SURMOUNT-5, the first large randomized head-to-head trial directly comparing tirzepatide (15 mg maximum) with semaglutide (2.4 mg maximum) in adults with obesity.
Results at 72 weeks:
Tirzepatide produced roughly 6.5 percentage points more weight loss on average — a clinically meaningful difference, but not a landslide. A substantial minority of semaglutide patients achieved weight loss in tirzepatide's range, and vice versa. Individual response matters more than the average gap.
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist (single pathway) | Dual GIP + GLP-1 receptor agonist |
| Brand names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Avg weight loss (trials) | 14.9% (STEP 1), 13.7% (SURMOUNT-5) | 22.5% (SURMOUNT-1), 20.2% (SURMOUNT-5) |
| Dose range | 0.25 – 2.4 mg/week | 2.5 – 15 mg/week |
| Titration length | ~16 weeks to max dose | ~16 weeks to max dose |
| Delivery | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Half-life | ~7 days | ~5 days |
| Side effects | GI (nausea, constipation, diarrhea) | GI (nausea, constipation, diarrhea) — similar |
| Cardiovascular outcome data | SELECT trial: 20% MACE reduction | SURPASS-CVOT ongoing |
| YourMD starting price | $149/month | $299/month |
| Brand-name cash price | ~$1,300/month (Wegovy) | ~$1,059/month (Zepbound) |
Both drugs cause the same family of GI side effects (nausea, constipation, diarrhea, reflux, fatigue, occasional vomiting). Both peak in the first 2–4 weeks after each dose increase. In SURMOUNT-5, discontinuation rates due to side effects were similar between the two arms. Individual tolerance varies — some patients sail through one drug but struggle with the other for reasons we cannot always predict. Starting low and going slow, with appropriate anti-nausea support if needed, solves most side effect issues regardless of which drug you choose.
Many YourMD patients follow this trajectory: start on semaglutide, lose 10–15% of body weight, plateau or decide they want more, and switch to tirzepatide for the final push. This pattern takes advantage of semaglutide's lower cost during the initial loss phase and tirzepatide's greater potency when progress stalls. Your physician can support either strategy.
Pick semaglutide if cost, safety track record, or modest weight loss goals are your priorities. Pick tirzepatide if maximum weight loss, diabetes treatment, or dual-mechanism pharmacology matters most to you. Both will be managed by a board-certified physician at YourMD, both ship from licensed US compounding pharmacies, both include live video consultations and unlimited messaging, and both can be switched if your first choice does not fit.
Both share the same class warnings: thyroid C-cell tumors in rodents (causal link in humans unconfirmed), pancreatitis, gallbladder disease. Contraindications are identical: personal or family history of medullary thyroid carcinoma, MEN 2, pregnancy, severe GI disease. Semaglutide has longer real-world safety data; tirzepatide's safety profile in trials is comparable.
No. Never combine GLP-1 agonists. If switching, stop one drug and start the other at the starter dose.
Our compounded medications are typically cash-pay. We can provide superbill documentation for HSA/FSA reimbursement. For patients with commercial insurance coverage of brand-name Wegovy or Zepbound, your physician can write for the brand and coordinate with specialty pharmacies, but this is a separate workflow from our compounded program.
Start with the eligibility screening. Your YourMD physician will discuss both options, your medical history, and your goals during your live consultation. Many patients walk in leaning one way and walk out with clarity after talking through their specific situation.
From $149/month
Best for first-time GLP-1 users and budget-conscious patients.
Start with SemaglutideFrom $299/month
Best for maximum weight loss, type 2 diabetes, or semaglutide plateau.
Start with TirzepatideNot sure? Start the free screening and your physician will help you choose.
Medical disclaimer: This page is educational and is not medical advice. Both medications are available only by prescription after a physician evaluation. Individual results vary. Side effects and contraindications are described on the individual medication pages. Page medically reviewed by Teja V. Surapaneni, MD, MS — Board-Certified Internal Medicine, licensed in Nevada, Washington, Oregon, and Wyoming.
Last reviewed: April 17, 2026